OGS reports pivotal data

Oxford GlycoSciences (LSE:OGS; OGSI) said preliminary analysis of a six-month, 36-patient pivotal study showed Vevesca oral N-butyldeoxynojirimycin glucosyltransferase inhibitor alone successfully mai...